$1.71 Billion is the total value of Cormorant Asset Management, LP's 49 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 45.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $464,099,700 | +11.8% | 8,142,100 | 0.0% | 27.07% | +16.4% | ||
| BBIO | Buy | BRIDGEBIO PHARMA INC | $122,950,916 | +71.5% | 4,662,530 | +11.8% | 7.17% | +78.5% |
| AMAM | Buy | AMBRX BIOPHARMA INCsponsored ads | $114,122,424 | -27.9% | 9,923,689 | +3.2% | 6.66% | -24.9% |
| Buy | ARCELLX INC | $77,142,000 | +22.0% | 2,150,000 | +7.5% | 4.50% | +27.0% | |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $76,080,000 | -36.2% | 2,000,000 | +52.7% | 4.44% | -33.6% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $57,403,500 | +38.0% | 3,850,000 | +1.3% | 3.35% | +43.6% |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $55,633,835 | +99.9% | 4,504,764 | +46.2% | 3.24% | +108.1% |
| Buy | STRUCTURE THERAPEUTICS INCsponsored ads | $53,262,327 | +122.3% | 1,056,373 | +83.3% | 3.11% | +131.5% | |
| BMEA | BIOMEA FUSION INC | $49,135,202 | -37.3% | 3,570,872 | 0.0% | 2.87% | -34.7% | |
| IMVT | Buy | IMMUNOVANT INC | $47,027,750 | +350.7% | 1,225,000 | +122.7% | 2.74% | +369.7% |
| TARS | Buy | TARSUS PHARMACEUTICALS INC | $46,582,669 | +81.4% | 2,621,422 | +84.4% | 2.72% | +88.8% |
| CABA | Buy | CABALETTA BIO INC | $43,824,833 | +52.8% | 2,879,424 | +29.6% | 2.56% | +59.1% |
| PCVX | VAXCYTE INC | $33,901,700 | +2.1% | 665,000 | 0.0% | 1.98% | +6.3% | |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $32,770,625 | – | 1,101,904 | +100.0% | 1.91% | – |
| IMMUNEERING CORP | $32,289,516 | -24.3% | 4,204,364 | 0.0% | 1.88% | -21.1% | ||
| PHVS | Buy | PHARVARIS N V | $28,413,670 | +92.8% | 1,361,460 | +39.8% | 1.66% | +100.6% |
| New | RAYZEBIO INC | $26,246,239 | – | 1,182,263 | +100.0% | 1.53% | – | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $25,568,000 | -8.2% | 3,200,000 | 0.0% | 1.49% | -4.4% | |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $23,672,600 | +36.5% | 140,000 | +75.0% | 1.38% | +42.1% |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $21,755,000 | – | 1,900,000 | +100.0% | 1.27% | – |
| ERASCA INC | $21,302,095 | -28.6% | 10,813,246 | 0.0% | 1.24% | -25.7% | ||
| AVTE | AEROVATE THERAPEUTICS INC | $21,192,215 | -20.9% | 1,561,696 | 0.0% | 1.24% | -17.6% | |
| New | MARINUS PHARMACEUTICALS INC | $21,131,250 | – | 2,625,000 | +100.0% | 1.23% | – | |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $19,486,250 | +97.0% | 850,000 | +41.7% | 1.14% | +105.2% |
| EWTX | EDGEWISE THERAPEUTICS INC | $16,885,663 | -26.1% | 2,946,887 | 0.0% | 0.98% | -23.0% | |
| Sell | ENLIVEN THERAPEUTICS INC | $16,620,286 | -57.9% | 1,216,712 | -37.2% | 0.97% | -56.2% | |
| PRAX | PRAXIS PRECISION MEDICINES I | $16,245,000 | +48.7% | 9,500,000 | 0.0% | 0.95% | +54.9% | |
| IDYA | IDEAYA BIOSCIENCES INC | $16,188,000 | +14.8% | 600,000 | 0.0% | 0.94% | +19.5% | |
| INSM | New | INSMED INC | $14,518,750 | – | 575,000 | +100.0% | 0.85% | – |
| ZNTL | Sell | ZENTALIS PHARMACEUTICALS INC | $14,042,000 | -54.5% | 700,000 | -36.1% | 0.82% | -52.7% |
| AXNX | Sell | AXONICS INC | $14,030,000 | -13.7% | 250,000 | -22.4% | 0.82% | -10.2% |
| LBPH | LONGBOARD PHARMACEUTICALS IN | $13,083,464 | -24.3% | 2,353,141 | 0.0% | 0.76% | -21.2% | |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $11,242,294 | -61.2% | 1,762,115 | -32.5% | 0.66% | -59.6% |
| DISC MEDICINE INC | $10,570,500 | +5.8% | 225,000 | 0.0% | 0.62% | +10.2% | ||
| COGT | COGENT BIOSCIENCES INC | $9,750,000 | -17.7% | 1,000,000 | 0.0% | 0.57% | -14.2% | |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $9,220,500 | -46.6% | 450,000 | -48.2% | 0.54% | -44.4% |
| GHRS | GH RESEARCH PLCordinary shares | $5,960,082 | -15.3% | 593,043 | 0.0% | 0.35% | -11.7% | |
| RAPT | RAPT THERAPEUTICS INC | $5,401,500 | -11.1% | 325,000 | 0.0% | 0.32% | -7.4% | |
| VERV | VERVE THERAPEUTICS INC | $4,641,000 | -29.3% | 350,000 | 0.0% | 0.27% | -26.4% | |
| STOK | STOKE THERAPEUTICS INC | $4,285,960 | -62.9% | 1,087,807 | 0.0% | 0.25% | -61.4% | |
| CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $3,633,552 | +4.5% | 561,600 | 0.0% | 0.21% | +8.7% | |
| VIGIL NEUROSCIENCE INC | $3,324,477 | -42.7% | 616,786 | 0.0% | 0.19% | -40.3% | ||
| ALXO | ALX ONCOLOGY HLDGS INC | $2,937,979 | -36.1% | 612,079 | 0.0% | 0.17% | -33.5% | |
| BIOHAVEN LTD | $2,131,858 | +8.7% | 81,963 | 0.0% | 0.12% | +12.7% | ||
| BCAB | BIOATLA INC | $2,007,896 | -43.3% | 1,181,115 | 0.0% | 0.12% | -40.9% | |
| New | NEUMORA THERAPEUTICS INC. | $1,302,256 | – | 92,293 | +100.0% | 0.08% | – | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $913,749 | -2.1% | 392,167 | 0.0% | 0.05% | +1.9% | |
| New | HARPOON THERAPEUTICS INC | $217,862 | – | 54,060 | +100.0% | 0.01% | – | |
| ORCHARD THERAPEUTICS PLCspon ads new | $198,383 | +48.4% | 25,664 | 0.0% | 0.01% | +71.4% | ||
| BCEL | Exit | ATRECA INC | $0 | – | -319,057 | -100.0% | -0.02% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -540,600 | -100.0% | -0.02% | – |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -199,547 | -100.0% | -0.03% | – |
| GLTO | Exit | GALECTO INC | $0 | – | -1,020,238 | -100.0% | -0.14% | – |
| Exit | GREENLIGHT BIOSCIENCS HLDS P | $0 | – | -9,188,659 | -100.0% | -0.15% | – | |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -645,000 | -100.0% | -0.19% | – |
| Exit | LEAP THERAPEUTICS INC | $0 | – | -1,073,046 | -100.0% | -0.19% | – | |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -39,000 | -100.0% | -0.20% | – |
| AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -115,000 | -100.0% | -0.30% | – |
| AVIR | Exit | ATEA PHARMACEUTICALS INC | $0 | – | -1,547,181 | -100.0% | -0.32% | – |
| ARQT | Exit | ARCUTIS BIOTHERAPEUTICS INC | $0 | – | -800,000 | -100.0% | -0.43% | – |
| Exit | ASTRIA THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.47% | – | |
| MORF | Exit | MORPHIC HLDG INC | $0 | – | -150,000 | -100.0% | -0.48% | – |
| Exit | LIANBIOsponsored ads | $0 | – | -4,250,000 | -100.0% | -0.54% | – | |
| ISEE | Exit | IVERIC BIO INCcall | $0 | – | -300,000 | -100.0% | -0.66% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INCput | $0 | – | -810,800 | -100.0% | -0.78% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -130,000 | -100.0% | -0.83% | – |
| VRDN | Exit | VIRIDIAN THERAPEUTICS INC | $0 | – | -850,000 | -100.0% | -1.13% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INC | $0 | – | -340,000 | -100.0% | -1.37% | – |
| ETNB | Exit | 89BIO INC | $0 | – | -1,350,000 | -100.0% | -1.43% | – |
| DSGN | Exit | DESIGN THERAPEUTICS INC | $0 | – | -5,150,000 | -100.0% | -1.82% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -1,500,000 | -100.0% | -2.32% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.